Author
Listed:
- Olga V. Marchenko
(Statistics and Data Insights Department, Bayer)
- Lisa M. LaVange
(Department of Biostatistics, University of North Carolina at Chapel Hill)
- Natallia V. Katenka
(University of Rhode Island, Department of Computer Science and Statistics)
Abstract
Biostatistics plays an important role in the design, conduct, and reporting of clinical trials. In recent years, the recognition and appreciation of biostatistics have greatly improved. Biostatisticians are not only responsible for the quantitative properties of clinical trial designs and for analyzing data from clinical trials, they are also respected partners of the clinical teams contributing to strategic discussions and helping solve day-to-day issues on studies and clinical programs. Biostatisticians also drive the development and implementation of innovative statistical methodology. This chapter provides a brief overview of basic biostatistical principles and analysis methods used in clinical trials. In the Introduction, we cover basic biostatistical principles of clinical trials including population and sample, errors and bias, choice of a control arm, randomization, allocation, and blinding. Phases of clinical development and commonly used statistical designs are described in Sect. 1.2. A brief overview of the most commonly used probability models and basic principles of estimation and inference with an emphasis on modeling techniques are given in Sect. 1.3. Where appropriate, references to available software procedures in R and/or SAS are provided. Finally, we highlight some important considerations for clinical trials, such as defining appropriate estimands, handling outcomes with missing data, applying multiplicity adjustments, analyzing subgroups, planning multiregional clinical trials, and evaluating drug safety.
Suggested Citation
Olga V. Marchenko & Lisa M. LaVange & Natallia V. Katenka, 2020.
"Biostatistics in Clinical Trials,"
Springer Books, in: Olga V. Marchenko & Natallia V. Katenka (ed.), Quantitative Methods in Pharmaceutical Research and Development, chapter 0, pages 1-70,
Springer.
Handle:
RePEc:spr:sprchp:978-3-030-48555-9_1
DOI: 10.1007/978-3-030-48555-9_1
Download full text from publisher
To our knowledge, this item is not available for
download. To find whether it is available, there are three
options:
1. Check below whether another version of this item is available online.
2. Check on the provider's
web page
whether it is in fact available.
3. Perform a
for a similarly titled item that would be
available.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:sprchp:978-3-030-48555-9_1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.